Special Issue

Application of Biostatistics in Cancer Research

Message from the Guest Editors

Advances in statistical methods and cancer research are intrinsically linked, driving forward innovations in both fields. In an era where experimental therapies are increasingly expensive, cutting-edge and efficient clinical trial designs are crucial.

Emerging technologies in radiomics, genomics, proteomics, metabolomics, and spatial transcriptomics demand sophisticated statistical and bioinformatics approaches. These include graphical models, machine learning, and artificial intelligence (AI). Moreover, new statistical methods in genome-wide association studies (GWASs) are instrumental in identifying individuals at increased risk of cancer, thereby enhancing prevention strategies and improving early detection through screening.

Additionally, the application of statistical approaches to natural language processing (NLP)—a technology that translates human language into machine-readable data—is a pioneering area in cancer research. This Special Issue will showcase breakthrough statistical methods poised to make a significant impact on advancing cancer research.

Guest Editors

Prof. Dr. Alan Hutson

Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA

Dr. Han Yu

Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA

Deadline for manuscript submissions

closed (30 June 2025)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/207156

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)